We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$846M
AUM Growth
-$143M
Cap. Flow
-$121M
Cap. Flow %
-14.3%
Top 10 Hldgs %
70.39%
Holding
52
New
24
Increased
5
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.4M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$36.8M
3
TGTX icon
TG Therapeutics
TGTX
+$19.2M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$18.7M
5
LRMR icon
Larimar Therapeutics
LRMR
+$13.8M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$147M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$51.4M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$21.1M
4
DYAX
DYAX CORPORATION
DYAX
+$21.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 53.83%
2 Miscellaneous 46.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
51
DELISTED
Immunomedics Inc
IMMU
– –
-1,000,000
Closed -$3.65M
RPRX
52
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-1,219,381
Closed -$21.1M
1 2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, RA Capital Management held 52 positions worth $846M, down 14% from $989M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $121M in Q3 2014, closing 6 positions and reducing 10 holdings. Its most notable exit was Repros Therapeutics Inc., an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 67% a quarter earlier, followed by Miscellaneous.

Against the trend, RA Capital Management opened a new position in AVANIR PHARMACEUTICALS, INC CL A worth $64.2M.

  • RA Capital Management's largest Q3 2014 buy was AVANIR PHARMACEUTICALS, INC CL A: 5,386,700 shares worth $64.2M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2014, an estimated $47.4M increase.
  • RA Capital Management's biggest Q3 2014 reduction was Achillion Pharmaceuticals, cutting an estimated $147M.
  • RA Capital Management fully exited Repros Therapeutics Inc. in Q3 2014, selling an estimated $21.1M.
  • RA Capital Management's ten largest holdings make up 70% of its $846M portfolio in Q3 2014.
  • RA Capital Management opened 24 new positions and closed 6 in Q3 2014.
  • RA Capital Management's portfolio value fell 14% quarter-over-quarter to $846M.

Based on RA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.